3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | 63214-60-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
• 英文别名: 3-methyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one；2,4,8-triaza-2-methyl-4-phenylspiro[4.5]decane-1-one
• CAS: 63214-60-8
• 化学式: C₁₄H₁₉N₃O
• 分子量: 245.324
• InChiKey: IGPACMIJADAUNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

MSDS英文版

反应信息

• 作为反应物：
  描述：

  3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 在 盐酸 、 sodium carbonate 、 potassium iodide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 8-{4-[2-(5-iodothienyl)]-4-oxo-butyl}-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
  参考文献：
  名称：

  Synthesis of [123I]-8-[4-[2-(5-iodothienyl)]-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one: A potential dopamine D2 receptor radioligand for SPECT

  摘要：

  [I-123]-8-[4-[2-(5-Iodothienyl)]-4-oxobutyl]-3-methyl-1 phenyl-1,3,8-triazaspiro[4.5]-decan-4-one ((1) under bar)) has been synthesized as a potential ligand for dopamine D-2 receptors. This new compound proved to be moderate in lipophilicity (log P = 3.14) and exhibited high affinity (Ki = 1.9 nM) for the dopamine D-2 receptor as well as good selectivity for D-2 versus serotonin 5HT(2) receptors (Ki 5HT(2)/D-2 = 16.7) in vitro. The corresponding radioligand, I-123-(1) under bar, was synthesized from a thienyl tributylstannane precursor using oxidative iododestannylation methods. The radiochemical yield was 64-808 EOS (n = 5) and the purified product was >99% radiochemically purity with a specific activity >3,500 mCi/mu mol(>129,500 MBq/mu mol).

  DOI：

  10.1002/(sici)1099-1344(199805)41:5<363::aid-jlcr90>3.0.co;2-b
• 作为产物：
  描述：

  tert-butyl-3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 以91%的产率得到3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
  参考文献：
  名称：

  Synthesis of [123I]-8-[4-[2-(5-iodothienyl)]-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one: A potential dopamine D2 receptor radioligand for SPECT

  摘要：

  [I-123]-8-[4-[2-(5-Iodothienyl)]-4-oxobutyl]-3-methyl-1 phenyl-1,3,8-triazaspiro[4.5]-decan-4-one ((1) under bar)) has been synthesized as a potential ligand for dopamine D-2 receptors. This new compound proved to be moderate in lipophilicity (log P = 3.14) and exhibited high affinity (Ki = 1.9 nM) for the dopamine D-2 receptor as well as good selectivity for D-2 versus serotonin 5HT(2) receptors (Ki 5HT(2)/D-2 = 16.7) in vitro. The corresponding radioligand, I-123-(1) under bar, was synthesized from a thienyl tributylstannane precursor using oxidative iododestannylation methods. The radiochemical yield was 64-808 EOS (n = 5) and the purified product was >99% radiochemically purity with a specific activity >3,500 mCi/mu mol(>129,500 MBq/mu mol).

  DOI：

  10.1002/(sici)1099-1344(199805)41:5<363::aid-jlcr90>3.0.co;2-b

文献信息

• 1-(1,2-disubstituted pipeidinyl)-4-substituted piperidine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06346540B1

  公开（公告）日：2002-02-12

  The present invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 0, 1 or 2; ═Q is ═O or ═NR3; X is a covalent bond or a bivalent radical of formula —O—, —S—, —NR3—; R1 is Ar1; Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent of formula —O—CH2—CH2—O— or —O—CH2—CH2—CH2—O—; R2 is Ar2; Ar2C1-6alkyl; Het or HetC1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 is hydrogen; C1-4alkyl; C1-4alkyloxyC1-4alkyl; hydroxyC1-4alkyl; carboxyl; C1-4alkyloxycarbonyl or Ar3; R5 is hydrogen; hydroxy; Ar3; Ar3C1-6alkyloxy; di(Ar3)C1-6alkyloxy; Ar3C1-6alkylthio; di(Ar3)C1-6alkylthio; Ar3C1-6alkylsulfoxy; di(Ar3)C1-6alkylsulfoxy; Ar3C1-6alkylsulfonyl; di(Ar3)C1-6alkylsulfonyl; —NR7R8; C1-6alkyl substituted with —NR7R8; or a radical of formula (a-1) or (a-2); R4 and R5 may also be taken together; R6 is hydroxy; C1-6alkyloxy; C1-6alkyl or Ar3C1-6alkyl; Ar1, Ar2 and Ar3 are phenyl or substituted phenyl; Ar2 is also naphtalenyl; and Het is an optionally substituted monocyclic or bicyclic heterocycle; as substance P antagonists; their preparation, compositions containing them and their use as a medicine.

  本发明涉及以下式的化合物 其中n为0、1或2；m为1或2，但如果m为2，则n为1；p为0、1或2；═Q为═O或═NR3；X为配位键或式的二价基团—O—、—S—、—NR3—；R1为Ar1；Ar1C1-6烷基或二(Ar1)C1-6烷基，其中每个C1-6烷基基团可选择地用羟基、C1-4烷氧基、氧代基或式的缩醛基团取代—O—CH2—CH2—O—或—O—CH2—CH2—CH2—O—；R2为Ar2；Ar2C1-6烷基；Het或HetC1-6烷基；R3为氢或C1-6烷基；R4为氢；C1-4烷基；C1-4烷氧基C1-4烷基；羟基C1-4烷基；羧基；C1-4烷氧羰基或Ar3；R5为氢；羟基；Ar3；Ar3C1-6烷氧基；二(Ar3)C1-6烷氧基；Ar3C1-6烷硫基；二(Ar3)C1-6烷硫基；Ar3C1-6烷磺氧基；二(Ar3)C1-6烷磺氧基；Ar3C1-6烷磺基；二(Ar3)C1-6烷磺基；—NR7R8；用—NR7R8取代的C1-6烷基；或式的基团(a-1)或(a-2)；R4和R5也可结合在一起；R6为羟基；C1-6烷氧基；C1-6烷基或Ar3C1-6烷基；Ar1、Ar2和Ar3为苯基或取代苯基；Ar2也为萘基；Het为可选择地取代的单环或双环杂环；作为P物质拮抗剂；它们的制备、含有它们的组合物以及它们作为药物的用途。
• Indol-3-yl-carbonyl-azaspiro derivatives
  申请人：Bissantz Caterina

  公开号：US20070072888A1

  公开（公告）日：2007-03-29

  This invention relates to indol-3-yl-carbonyl-azaspiro derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the azaspiro-head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.

  本发明涉及一种表示为式I的indol-3-yl-carbonyl-azaspiro衍生物，其作为V1a受体拮抗剂，其中azaspiro头基团A和残基R1，R2和R3如此定义。本发明还涉及含有这种化合物的制药组合物，其用于治疗痛经、高血压、慢性心力衰竭、不适当的加压素分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症，并且涉及其制备方法。
• Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
  申请人：——

  公开号：US20040087574A1

  公开（公告）日：2004-05-06

  Disclosed are novel spiro derivatives and their medical uses, especially as adhesion molecule inhibitors useful for therapies of inflammatory diseases. The spiro derivative according to the present invention has the chemical structure, for example, represented by the following Formula (31): 1

  本发明涉及新型螺环衍生物及其医药用途，特别是作为黏附分子抑制剂用于治疗炎症性疾病。根据本发明，所述螺环衍生物具有化学结构，例如由以下公式（31）表示：1。
• SPIRO DERIVATIVES AND ADHESION MOLECULE INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1489081A1

  公开（公告）日：2004-12-22

  Disclosed is the use of an adhesion molecule inhibitor that is effective in the prevention and treatment of inflammatory diseases caused by infiltration of leukocytes such as monocytes, lymphocytes and eosinophils, by inhibiting cell infiltration which mediates adhesion molecules, especially adhesion molecule VLA-4. Since the spiro acid derivatives according to the present invention are excellent in the effect of inhibiting cell adhesion via adhesion molecules, especially adhesion molecule VLA-4, they are useful as therapeutic drugs against various inflammatory diseases. For example, provided are the spiro derivative and the adhesion molecule inhibitor which includes as an active ingredient the spiro derivative as shown by the below formula (18).

  本发明公开了一种粘附分子抑制剂，通过抑制介导粘附分子（尤其是粘附分子 VLA-4）的细胞浸润，可有效预防和治疗由单核细胞、淋巴细胞和嗜酸性粒细胞等白细胞浸润引起的炎症性疾病。 由于本发明的螺酸衍生物在抑制细胞通过粘附分子（尤其是粘附分子 VLA-4）的粘附方面具有出色的效果，因此可作为治疗药物用于各种炎症性疾病。例如，本发明提供了螺衍生物和粘附分子抑制剂，其活性成分包括如下式（18）所示的螺衍生物。
• Substituted spirocyclic inhibitors of autotaxin
  申请人：X-Rx, Inc.

  公开号：US10011601B2

  公开（公告）日：2018-07-03

  The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.

  本发明涉及根据式 1 的化合物和药学上可接受的盐、合成、中间体、制剂以及用其治疗疾病的方法，包括至少部分由 ATX 介导的癌症、淋巴细胞归巢、慢性炎症、神经性疼痛、纤维化疾病、血栓形成和胆汁淤积性瘙痒症。